According to a real-world multi-institutional cohort study, 22% of patients who received PD-1/PD-L1 inhibitors suffered from pneumonitis, and patients with pneumonitis showed an increased risk of death (hazard ratio [HR]: 2.34, 95% confidence interval [CI] 1.47–3.71). Here, CD274 is linked to pneumonitis.